Cargando…

Early low blood MALT1 expression levels forecast better efficacy of PD‑1 inhibitor‑based treatment in patients with metastatic colorectal cancer

Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) modulates colorectal cancer (CRC) malignant behaviors and tumor immune escape. The present study aimed to explore the association of MALT1 with treatment response and survival time among patients with metastatic CRC (mCRC) af...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Chuanming, Yu, Fan, Xu, Wanli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320427/ https://www.ncbi.nlm.nih.gov/pubmed/37415633 http://dx.doi.org/10.3892/ol.2023.13915

Ejemplares similares

Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer
por: Chen, Beibei, et al.
Publicado: (2022)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
por: Sun, Liying, et al.
Publicado: (2021)

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
por: Oliveira, André F., et al.
Publicado: (2019)

Metastatic sites and lesion numbers cooperated to predict efficacy of PD‐1 inhibitor‐based combination therapy for patients with metastatic colorectal cancer
por: Jiang, Weiqin, et al.
Publicado: (2023)

A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer
por: Fan, Zhongyuan, et al.
Publicado: (2019)

In silico study on identification of novel MALT1 allosteric inhibitors
por: Zhang, Jinrui, et al.
Publicado: (2019)

Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis
por: Zhang, Xiao, et al.
Publicado: (2022)

The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
por: Wen, Lu, et al.
Publicado: (2021)

The Paracaspase MALT1 in Cancer
por: Gomez Solsona, Beatriz, et al.
Publicado: (2022)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
por: Page, David B., et al.
Publicado: (2019)

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2023)

PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed
por: Huang, Weijia, et al.
Publicado: (2022)

Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis
por: Sun, Leitao, et al.
Publicado: (2020)

Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer
por: Mo, Dun-Chang, et al.
Publicado: (2022)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2021)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
por: Qi, Yihang, et al.
Publicado: (2021)

PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors
por: Rosell, Rafael, et al.
Publicado: (2015)

Mechanism and specificity of the human paracaspase MALT1
por: Hachmann, Janna, et al.
Publicado: (2012)

Attacking MALT1 for ABC-DLBCL therapy
por: Krappmann, Daniel
Publicado: (2012)

Targeting Lymphomas Through MALT1 Inhibition
por: Fontan, Lorena, et al.
Publicado: (2012)

Immunodeficiency and CARD-BCL10-MALT1
por: Pérez de Diego, Rebeca
Publicado: (2015)

MALT1 is an intrinsic regulator of regulatory T cells
por: Brüstle, A, et al.
Publicado: (2017)

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
por: Elias, Rawad, et al.
Publicado: (2018)

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
por: Tang, Hui, et al.
Publicado: (2022)

Two Antagonistic MALT1 Auto-Cleavage Mechanisms Reveal a Role for TRAF6 to Unleash MALT1 Activation
por: Ginster, Stefanie, et al.
Publicado: (2017)

Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
por: Zhou, Zi‐Chao, et al.
Publicado: (2022)

Glutaminolysis Mediated by MALT1 Protease Activity Facilitates PD-L1 Expression on ABC-DLBCL Cells and Contributes to Their Immune Evasion
por: Xia, Xichun, et al.
Publicado: (2018)

MALT report
por: Smith, Tim, et al.
Publicado: (2021)

Malt Extract
por: Ebert, Albert E.
Publicado: (1870)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Blood MALT1, Th1, and Th17 cells are dysregulated, inter‐correlated, and correlated with disease activity in rheumatoid arthritis patients; meanwhile, MALT1 decline during therapy relates to treatment outcome
por: Ye, Zhuang, et al.
Publicado: (2021)

PD-1 inhibitors-based second-line therapy for metastatic gastric cancer
por: Gou, Miaomiao, et al.
Publicado: (2023)

Masking MALT1: the paracaspase's potential for cancer therapy
por: Vucic, Domagoj, et al.
Publicado: (2009)

Backbone Assignment of the MALT1 Paracaspase by Solution NMR
por: Unnerståle, Sofia, et al.
Publicado: (2016)

MALT1 protease activity in primary effusion lymphoma
por: Juilland, Mélanie, et al.
Publicado: (2017)

PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
por: Luo, Min, et al.
Publicado: (2021)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ke5j78rl8oacimf1cddulud3ln